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Aims Cardiac resynchronization therapy (CRT) has dramatically improved the symptoms and prognosis of patients with
heart failure in large randomized clinical trials. Optimization of device settings may maximize beneﬁt on an individual
basis, although the best method for this is not yet established. We evaluated the use of cardiogenic impedance
measurements (derived from intracardiac impedance signals) in CRT device optimization, using invasive left ventricu-
lar (LV) dP/dtmax as the reference.
Methods
and results
Seventeen patients underwent invasive haemodynamic assessment using a pressure wire placed in the LV cavity at the
time of CRT device implantation. Intracardiac impedance measurements were made at different atrioventricular (AV)
and interventricular (VV) delays and compared with LV dP/dtmax. We assessed the performance of patient-speciﬁc
and generic impedance-based models in predicting acute haemodynamic response to CRT. In two patients, LV
catheterization with the pressure wire was unsuccessful and in two patients LV lead delivery was unsuccessful; there-
fore, data were acquired for 13 out of 17 patients. Left ventricular dP/dtmax was 919+182 mmHg/s at baseline and
this increased acutely (by 24%) to 1121+226 mmHg/s as a result of CRT. The patient-speciﬁc impedance-based
model correctly predicted the optimal haemodynamic response (to within 5% points) for AV and VV delays in 90
and 92% of patients, respectively.
Conclusion Cardiogenic impedance measurements are capable of correctly identifying the maximum achievable LV dP/dtmax as
measured by invasive haemodynamic assessment. This study suggests that cardiogenic impedance can potentially
be used for CRT optimization and may have a role in ambulatory assessment of haemodynamics.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Cardiac resynchronization therapy (CRT) has dramatically
improved both symptoms and prognosis in patients with heart
failure,
1–5 although a signiﬁcant proportion of patients do not
derive clear clinical beneﬁt.
6 Given that the principal mechanism
of CRT is to restore cardiac synchrony, an important approach
to increase clinical beneﬁt from CRT is optimization of device pro-
gramming, so as to establish the atrioventricular (AV) and interven-
tricular (VV) delays that give maximal improvement in cardiac
function. Acute improvement in systolic function has been demon-
strated as a result of optimization of AV and VV delays at the time
of CRT implantation.
7,8 Several small studies have shown improve-
ments in acute haemodynamics or myocardial efﬁciency as a result
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9–11 Moreover, optimization of device set-
tings in CRT is an inherent part of evidence-based practice, given
that it was performed in the landmark clinical trials that demon-
strated the clinical beneﬁt of CRT.
1,3,4,6 With large numbers of
CRT implantation procedures being performed
12 and the potential
for device optimization to be performed at various intervals during
clinical follow-up,
13 CRT optimization has major ﬁnancial impli-
cations. However, the best method for device optimization is
not yet established. The optimal method should be clinically
relevant, non-invasive, reproducible, and quick to perform in the
outpatient setting. Echocardiographic optimization is commonly
used, but is time consuming and operator dependent. Invasive
haemodynamic assessment remains the gold standard, but this
carries procedural risks and is not ideally suited for the outpatient
setting, or for repeated optimizations to be performed at different
time intervals during clinical follow-up.
To date, the majority of published data regarding the use of
impedance measurements for device optimization relate to impe-
dance cardiography. This technique is based on measurements of
trans-thoracic impedance. This approach for CRT device optimiz-
ation had a good correlation with echo-derived optimal AV
delays
14 but was less accurate for VV optimization when compared
with invasive haemodynamics as the gold standard.
15 Inaccuracy
may arise as this technique is affected by changes in ﬂow in the
great vessels as well as variations in electrode positions, thoracic
anatomy, respiration, and external factors such as humidity and
skin temperature.
16 This brings into question the reliability of impe-
dance cardiography for CRT device optimization. In contrast, one
might expect cardiogenic impedance measurements, derived from
recordings taken at endocardial or epicardial sites, to be a more
speciﬁc reﬂection of volumetric changes in the heart.
We assessed a novel approach based on the fact that cardiogenic
impedance can be derived from intracardiac impedance signals. Car-
diogenic impedance reﬂects the volumetric ﬂuctuations within the
heart during the cardiac cycle and has been used to monitor
cardiac contraction in an animal model.
17 This method therefore
has the potential to be used for device optimization and may be per-
formed using the device alone, without other speciﬁc equipment.
Furthermore, as the impedance data are acquired from leads posi-
tioned within and on the surface of the heart, this technique
should be more speciﬁc than the use of trans-thoracic impedance.
We evaluated the feasibility of using cardiogenic impedance as a
marker for acute haemodynamic response to CRT. We also evalu-
ated its use for CRT device optimization with invasive left ventricu-
lar maximum pressure gradient (LV dP/dtmax)a sar e f e r e n c e .
Methods
Patients
The study was a prospective, non-randomized, multi-centre feasibility
study. Patients were enrolled in two centres: St Thomas’ Hospital,
London, and Uppsala University Hospital, Sweden. The local hospital
ethics committees approved the study, which complied with the
Declaration of Helsinki.
Patients were enrolled if they fulﬁlled criteria for CRT-D device
implantation and gave written informed consent. Exclusion criteria
were contra-indication for left heart catheterization or anticoagulation,
pregnancy, third-degree AV block, or indication for cardiac transplan-
tation. The patients were observed at enrolment, at implantation,
and on one additional occasion prior to hospital discharge.
Hypothesis
The study was designed to evaluate the following hypotheses:
(i) recording cardiogenic impedance measurements through the
CRT-D device at the time of the implantation procedure is feasible,
(ii) there is a correlation between cardiogenic impedance parameters
and invasive haemodynamic measurements (LV dP/dtmax) acquired
during the time of the implantation procedure, and (iii) cardiogenic
impedance could be used to perform AV and VV optimizations at
the time of CRT implant.
Implant protocol
Venous access was established using either the cephalic or the sub-
clavian vein, and the pocket for the device was made. Following this,
arterial access was obtained from either the radial or the femoral
artery using a 5F sheath. A long exchange wire was passed retrogradely
across the aortic valve into the LV cavity using a pigtail catheter. This
was then exchanged for a multi-purpose catheter, which was used to
pass a pressure wire (RadiTM wire, Radi Medical Systems, Uppsala,
Sweden) into the LV cavity. In order to minimize the potential risk
of any thrombo-embolic complications from the pressure wire in the
systemic circulation, a 2500 U heparin bolus was administered, fol-
lowed by a slow infusion of heparinized saline (500 U per 500 mL).
A PromoteTM CRT-D device (St Jude Medical, Sylmar, CA, USA), LV
and right ventricular (RV) leads were implanted in all patients. An
atrial lead was implanted in patients in sinus rhythm at baseline.
Data acquisition
The pressure wire is a ﬁne-calibre (0.014-inch) high-ﬁdelity wire that
has a torque similar to an angioplasty wire. There is a pressure
sensor located 30 mm from its tip. This was used to record intraven-
tricular pressure with a frequency response of 400 Hz. The output
from the pressure wire was connected to a Radi analyzer
w and con-
nected to a computer with PhysioMon
w software to give curves
showing real-time blood pressure and LV dP/dtmax.
The Promote device includes an impedance sensor. The device is
able to measure the impedance between several electrode surfaces
(device case, tip electrodes, ring electrodes, and coils of the high-
voltage lead) within the pulse generator system. To obtain an impe-
dance measurement, the device delivers a continuous sequence of sub-
threshold current impulses between two selected electrodes. It is a tri-
phasic, charge-balanced pulse with +850/2125 mA and a pulse dur-
ation of 19 ms. These pulses are emitted at 128 Hz. The impedance
was calculated by Z ¼ u/i (where Z is impedance, u is voltage, and i
is current).
Once the pacing electrodes were in satisfactory positions and with
good pacing and sensing parameters, the AV (in patients implanted
with an atrial lead) and VV delays were varied according to the proto-
col shown in Figure 1.
This protocol was designed to cause variation in haemodynamics
rather than to reﬂect a clinical optimization procedure (which would
have a narrower range of AV and VV delay values). This was done so
that comparison could be made across a larger spectrum of invasive
haemodynamic data along with the cardiogenic impedance data acquired.
At each device setting, recordings were made after 1 min of pacing
in atrial and ventricular pacing, atrial and ventricular sensing and dual
response (DDD) mode at a rate of 10 bpm above intrinsic, once
steady state pacing was achieved. Left ventricular dP/dtmax was
Intracardiac impedance and LV contractility 985recorded beat by beat for 1 min and two separate sets of cardiogenic
impedance parameter data were recorded beat by beat for ≥20 s
each. These sequences were each summarized with a median value.
Cardiogenic impedance vectors
Two different impedance vectors were used in the protocol: V1 (with
injection of the measurement current from RVring to LVring and
voltage sensing from RVtip to LVtip) and V3 (with injection of the
measurement current from RVring to RVtip and voltage sensing
from RVring to RVtip). It is important to note that the use of impe-
dance monitoring does not affect the choice of pacing vectors available
or the pacing functions of the device.
Cardiogenic impedance characteristics and
development of impedance-based models
Example data are shown in Figure 2.
The main characteristics inherent in the impedance waveform
were peak-to-peak, slope (dZ/dt), fractionation, diastolic dispersion,
and the average value of the impedance containing the DC
component, Z_0.
The impedance waveform was therefore quantiﬁed using these
characteristics. The impedance waveform—and the resulting charac-
teristics—varied substantially between patients. This is exempliﬁed
by comparison of Patients 2 and 4. In Patient 2, the maximum
rate of change of V3 occurred during ventricular diastole [decline
of left ventricular pressure (LVP)] whereas for Patient 4, the
maximum rate of change of V3 occurred during ventricular systole
(rise in LVP). However within each patient, the impedance charac-
teristics were remarkably reproducible.
For this reason, a patient-speciﬁc model was developed for each
subject. This incorporated a different weighting of the various impe-
dance characteristics for each patient, according to their relative con-
tributions to explain the variation of LV dP/dtmax. This was calculated
using a partial least-squares regression model in which each impedance
characteristic was assigned a coefﬁcient so that the sum of the
impedance characteristics was ﬁtted to describe the measured LV
dPdtmax. In this way, the patient-speciﬁc model was calibrated to a
haemodynamic reference.
For the patient-speciﬁc models, the contribution of different impe-
dance characteristics in predicting LV dP/dtmax varied; therefore, the
regression coefﬁcient values differed between patients.
A generic impedance-based model was also developed, in which
data were centred patient by patient in order to normalize for inter-
patient variability, and then the same coefﬁcient values were used
for all patients. The generic model did not require patient-speciﬁc
calibration to a haemodynamic reference.
In order to compare measurements taken during different device
settings and at different time points and to suppress variation due to
respiratory motion, the recordings were averaged into waveform tem-
plates that are representative of one cardiac cycle. The template wave-
forms were normalized for time and amplitude. This was done because
of intra- and interpatient variation in the R–R interval.
Impedance-based models used to predict
haemodynamic response
The patient-speciﬁc and generic models were applied to predict a
value for LV dP/dtmax at each step in the AV and VV optimization.
The LV dP/dtmax was predicted on the basis of impedance values
and waveform characteristics and this was compared with the LV
dP/dtmax measured invasively.
We compared the following outcomes for predicted vs. measured LV
dP/dtmax values: (i) programming difference in milliseconds and (ii) differ-
ence in percentage increase in LV dP/dtmax from intrinsic rhythm.
Data analysis and statistical analysis
Data are presented as mean+standard deviation (SD). In analyses at
patient level, these are mean and SD of beat-by-beat values. In analyses
at group level, these are mean and SD of patient values. Statistical
analysis was performed using paired t-tests. A P value of ,0.05 was
considered statistically signiﬁcant.
Results
Patient demographics are summarized in Table 1.
Procedural success
Seventeen patients were enrolled. In two of the patients (7 and 17),
LV catheterization with the pressure wire was unsuccessful and
therefore no LV pressure data were recorded. In Patients 3 and
13, LV lead implantation was unsuccessful, and these patients
were scheduled for a redo procedure for LV lead implantation
and were excluded from the analysis.
Haemodynamic response to cardiac
resynchronization therapy
The mean LV dP/dtmax in intrinsic rhythm for the study group of
13 patients was 919+182 mmHg/s and increased with CRT to
1136+247 mmHg/s (P , 0.01). The average acute increase in
LV dP/dtmax by optimized CRT when compared with intrinsic
rhythm was 24+22%.
Using a cut-off value of 10% increase in dP/dtmax from baseline
as a marker of acute response to CRT, 10 out of 13 patients
(77%) acutely responded. The magnitude of increase in LV
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Figure 1 Protocol for atrioventricular and interventricular
optimization.
M.R. Ginks et al. 986dP/dtmax from baseline in the responder group ranged from 11 to
62% (mean 31%). In the three non-responders the mean increase
was 5%.
Effect of optimizing atrioventricular
and interventricular delays
Three patients had atrial ﬁbrillation and were therefore not
included in the AV delay protocol. The optimal paced AV delay
in 10 patients included in the analysis was 141+41 ms (range
50–200 ms). Biventricular pacing with optimization of the paced
AV delay improved haemodynamics from 935+186 mmHg/s at
baseline to 1150+248 mmHg/s (P , 0.05).
The optimal VV delay in 13 patients analysed was LV ﬁrst by
35+33 ms (range LV ﬁrst by 80 to 0, also one RV only and
one LV only). Haemodynamics improved further from 1106+
236 mmHg/s with zero VV delay to 1121+226 mmHg/s as a
result of VV delay optimization. However, this slight improvement
was not statistically signiﬁcant.
Patient-speciﬁc cardiogenic impedance
model for atrioventricular and
interventricular delay optimization
The results of the haemodynamic response to AV delay optimiz-
ation are shown in Table 2. Data are shown for 10 patients.
There are two numbers in each cell on the left side of the table:
(i) the LV dP/dtmax value achieved with the AV setting suggested by
the method (reference or impedance) and (ii) the corresponding
‘clinical beneﬁt’ value in parentheses. The clinical beneﬁt is
deﬁned as the percentage change in LV dP/dtmax from intrinsic
rhythm. For the patient with second-degree AV block, the
change from the minimum LV dP/dtmax was used.
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Figure 2 Simultaneous data sets are shown for Patients 2 (left) and 4 (right). These include (from top to bottom in the ﬁgure) the surface
electrocardiogram, right ventricular bipolar electrogram, V1 impedance waveform, V3 impedance waveform, and left ventricular pressure trace.
Table 1 Patient demographics
Age 66+12 years
Male/female 14/3 (82/18%)
Cardiomyopathy
Ischaemic 12 (71%)
Dilated (non-ischaemic) 5 (29%)
Hypertrophic 0 (0%)
LV ejection fraction 23+6%
NYHA functional class 2.8+0.4
Heart failure medications
Beta-blockers 12 (71%)
ACE/ARB 17 (100%)
Diuretics 14 (82%)
Digitalis 7 (50%)
ECG characteristics
Intrinsic heart rate 72+19 bpm
Atrial ﬁbrillation 5 (29%)
QRS duration 150+27 ms
Baseline LV dP/dtmax 919+182 mmHg/s
NYHA, New York Heart Association; ACE, angiotensin-converting enzyme; ARB,
angiotensin receptor blocker.
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The patient-speciﬁc impedance-based model identiﬁed the
optimal setting for the AV delay in 9 of 10 patients to within 5%
points (of change in dP/dtmax from intrinsic rhythm). In Patient
14, the difference between impedance-predicted LV dP/dtmax and
the measured LV dP/dtmax was 56 mmHg/s (7%) and the discre-
pancy from optimal AV delay was one interval in the protocol.
The results for the VV delay optimization are shown in Table 3.
These data are displayed in Figure 3B. The variation in acute clini-
cal beneﬁt, that is the percentage increase in reference LV dP/dtmax,
is shown as a bar, and the red diamond displays the value obtained
with the setting selected by the impedance-based LV dP/dtmax
optimization.
For the VV optimization, the impedance-based model correctly
identiﬁed the optimal VV delay in 12 of 13 patients to within 5%
points. In the remaining patient (Patient 9), the discrepancy
between the impedance-predicted LV dP/dtmax and the measured
value was 40 mmHg/s (6%) and the difference between the
optimal value and that predicted by the model was 20 ms, one
increment in the VV optimization protocol.
Generic cardiogenic impedance model
for atrioventricular and interventricular
delay optimization
Results for the application of the generic impedance-based predic-
tion model for the whole patient group are shown in Figure 3C.
The generic model yielded predictions that were far less accu-
rate than the patient-speciﬁc model. This approach identiﬁed the
optimal VV delay in only 2 of 13 patients.
Discussion
The main ﬁndings of this study are that: (i) it is feasible to derive
cardiogenic impedance measurements from the lead impedance
measurements using a CRT-D device; (ii) the patient-speciﬁc
model was accurate in predicting the optimal AV and VV delays
during device optimization, using the invasive LV dP/dtmax as a
reference; and (iii) the generic impedance-based model was rela-
tively poor in predicting the optimal AV and VV delays.
This study suggests that impedance parameters that can be
readily obtained from a CRT-D device may be used for prediction
of optimal AV and VV delays. However, it seems that a patient-
speciﬁc model is needed for accurate prediction of optimal
device settings. The patient-speciﬁc model was made using
several characteristics of the impedance waveform. In 9 of 10
cases for the AV delay and 12 of 13 patients for the VV delay,
the patient-speciﬁc model predicted acute haemodynamic
response to within 5% points of the optimal response based on
invasive haemodynamics alone. The patient-speciﬁc model may
therefore represent a clinically effective tool for device optimiz-
ation. In contrast, the generic impedance-based model was difﬁcult
to construct, owing to substantial variability in impedance wave-
forms between different individuals. Furthermore, the accuracy
of the generic impedance-based model in predicting optimal AV
and VV intervals was poor.
Preliminary work using cardiogenic impedance has previously
been performed in animal models of heart failure. Stahl et al.
17
showed a strong correlation between intracardiac impedance par-
ameters and stroke volume in a porcine model. Panescu et al.
18
examined multiple impedance vectors derived from implanted biven-
tricular implantable cardioverter-deﬁbrillator devices in a canine/
ovine model of heart failure, and demonstrated good correlation
between cardiogenic impedance and progression of heart failure.
One recent study in humans has shown the feasibility of cardio-
genic impedance measurements in patients with non-ischaemic
cardiomyopathy, either in the setting of an electrophysiologic
study or at CRT device implantation.
19 This study used an external
purpose-built device for impedance measurements and the ﬁndings
suggested that cardiogenic impedance signals correlate well with
invasive haemodynamics.
In our study using impedance measurements via the CRT device
itself, the mean improvement in acute haemodynamics resulting
from CRT compared with baseline was 24+22%. This is in line
with ﬁndings from several other studies that used invasive LV
dP/dtmax as an outcome measure.
15,19–21
.......................................................................................... ....................................................................
...............................................................................................................................................................................
Table 2 Effect of optimization of atrioventricular delay
Patient LV dPdtmax (clinical beneﬁt) AV delay
Reference (mmHg/s) Impedance (mmHg/s) Difference (mmHg/s) Reference (ms) Impedance (ms) Difference (ms)
Pat01 1077 (4%) 1077 (4%) 0 (0%) 160 160 0
Pat04 1206 (3%) 1204 (3%) 2 (0%) 200 200 0
Pat05 1434 (25%) 1431 (25%) 3 (0%) 160 160 0
Pat06 928 (16%) 928 (16%) 0 (0%) 120 120 0
Pat09 628 (21%) 628 (21%) 0 (0%) 160 160 0
Pat10 1051 (24%) 1051 (24%) 0 (0%) 120 120 0
Pat11 1103 (2%) 1102 (2%) 1 (0%) 160 160 0
Pat12 1355 (14%) 1355 (14%) 0 (0%) 120 120 0
Pat14 1352 (58%) 1296 (51%) 56 (7%) 160 200 240
Pat15 1368 (66%) 1368 (66%) 0 (0%) 50 50 0
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Figure 3 (A) Graph of the atrioventricular delay optimization based on patient-speciﬁc impedance-based prediction models (red diamonds)
and comparison with the range of measured values across all settings (blue bars). (B) Graph of the interventricular delay optimization based on
patient-speciﬁc impedance-based prediction models (red diamonds) and comparison with measured values (blue bars). (C) Graph of the inter-
ventricular delay optimization based on the generic impedance-based prediction models and comparison with measured values.
Intracardiac impedance and LV contractility 989A limitation of this study is that it involved a small number of
patients. The principal aim of the study was to establish the feasi-
bility of cardiogenic impedance measurement using the CRT-D
device, and we therefore used a wider range of AV delays than
would be applied in clinical practice. We used invasive LV
dP/dtmax as this is widely regarded as the gold standard for refer-
ence purposes, and is a reproducible and operator-independent
marker of LV contractility. One limitation of the patient-speciﬁc
impedance-based model we developed is that it relies on an inva-
sive reference value, and it has not been established whether a
non-invasive reference may be used as a surrogate for this in the
patient-speciﬁc model. However, there is a good correlation
between invasively and non-invasively derived LV dP/dt,
22 so one
would anticipate that the impedance model can be calibrated in
this way.
In view of the fact that LV dP/dtmax is affected by heart rate, we
attempted to minimize the impact of heart rate on haemodynamic
response by pacing just above the intrinsic rate. However, any
increase in heart rate may alter the optimal AV and VV delays. Fur-
thermore, our optimization protocol was performed with the
patient supine, as necessitated by invasive haemodynamic monitor-
ing. This did not allow us to assess the effect of exercise on optimal
device settings, but our intention was primarily to assess the
validity of cardiogenic impedance as an approach to optimization.
Cardiogenic impedance monitoring itself may then be evaluated
in the ambulatory setting in a subsequent study.
Suggestions for further research
Further studies are needed to assess the clinical utility of cardio-
genic impedance-based device optimization. This should be in
the form of a large randomized trial evaluating the performance
of the patient-speciﬁc impedance-based model against the gold
standard in the outpatient setting of echocardiographic optimiz-
ation. Key questions are: does the impedance-based approach
identify the optimal AV and VV delays in large numbers of patients?
Is the outcome of patients whose devices are optimized using car-
diogenic impedance equivalent to the outcome of those optimized
using echocardiography? If that is found to be the case, there may
be a cost beneﬁt in device-based optimization, which requires
fewer resources.
Conclusions
We have demonstrated the feasibility of recording cardiogenic
impedance measurements through the CRT-D device at the time
of implantation.
The development of a generic impedance-based model was
challenging, and did not give a clinically useful platform for device
optimization.
A patient-speciﬁc impedance-based model was capable of accu-
rate prediction of the optimal AV and VV delays during device
optimization and may have a future role in clinical practice.
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